CoChat

A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials

Open access
Pais, Raluca, Cariou, Bertrand, Noureddin, Mazen, Francque, Sven, Schattenberg, Jörn M., Abdelmalek, Manal F., Lalazar, Gadi, Varma, Sharat, Dietrich, Julie, Miller, Veronica, Sanyal, Arun, Ratziu, Vlad · 2023 · Journal of Hepatology
Cited by 15

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

The current document has been issued by the Liver Forum who mandated the NAFLD-Associated Comorbidities Working Group - comprised of multi-stakeholder, academic, industry and patient associations to identify aspects of diverse comorbidities frequently associated with NASH that can interfere with the conduct of therapeutic trials and, in particular, impact efficacy and safety results. The objective of this paper is to propose guidance for the management of relevant comorbidities in both candidates and actual participants in NASH therapeutic trials. We relied on specific guidelines from scientific societies, when available, but adapted them to the particulars of NASH trials with the optics of addressing multiple interacting requirements such as maintaining patient safety, reaching holistic therapeutic objectives, minimizing confounding effects on efficacy and safety of investigational agents and allowing trial completion. We divided the field of action in, first, analyzing and stabilizing the patient's condition before inclusion in the trial and, second, managing comorbidities during the trial conduct. For the former, we discussed the concept of acceptable vs optimal control of comorbidities, defined metabolic and ponderal stability prior to randomization and weighed the pros and cons of a run-in period. For the latter, we analyzed non-hepatological co-morbid conditions for changes or acute events possibly occurring during the trial, including changes in alcohol consumption, in order to suggest when specific interventions are necessary and how to manage concomitant drug intake in line with methodological constraints. These recommendations are open to further refinement when additional data will become available and intend to provide a guide for clinical trialists in order to achieve optimal trial objectives while maintaining overall patient health and safety during the trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2023.03.014

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 15

Metadata

Authors
Pais, R., Cariou, B., Noureddin, M., Francque, S., Schattenberg, J. M., Abdelmalek, M. F., Lalazar, G., Varma, S., Dietrich, J., Miller, V., Sanyal, A., & Ratziu, V.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2023-09
Volume
79
Issue
3
Pages
829-841
ISSN
0168-8278 (ISSN-L)
OpenAlex
W4361197023
Cited by
15
References
34
FWCI
2.51
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials. https://app.cochat.ai/papers/10.1016/j.jhep.2023.03.014
The paper
Pais, R., Cariou, B., Noureddin, M., Francque, S., Schattenberg, J. M., Abdelmalek, M. F., Lalazar, G., Varma, S., Dietrich, J., Miller, V., Sanyal, A., & Ratziu, V. (2023). A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2023.03.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.